Vertex Pharmaceuticals Reports Q3 2025 Revenue Increase to $3.08 Billion, Refines Full-Year Guidance

Vertex Pharmaceuticals (VRTX.US) announced its third-quarter 2025 financial results, reporting total revenue of $3.08 billion, an 11% increase compared to the third quarter of 2024. Non-GAAP net income for the quarter was $1.2 billion, up from $1.1 billion in the prior-year period. Non-GAAP diluted EPS for Q3 2025 was $4.80, surpassing the analyst estimate of $4.55 per share.

Key Business Highlights

Total revenue growth was primarily driven by the continued strong performance of cystic fibrosis (CF) therapies and early contributions from CASGEVY and JOURNAVX launches. U.S. revenue increased 15% to $1.98 billion, fueled by robust CF patient demand, including ALYFTREK, and favorable net pricing. International revenue rose 4% to $1.10 billion due to solid performance across multiple regions.

The company's R&D; pipeline continues to advance, with five programs in pivotal development. Significant progress includes the completion of full enrollment for the povetacicept Phase 3 IgAN trial, with the first module of the BLA submission on track for FDA submission by the end of 2025. Additionally, the Phase 2/3 study of povetacicept in primary membranous nephropathy has commenced.

Refined Full-Year 2025 Financial Guidance

Vertex refined its full-year 2025 revenue guidance, now expecting total revenue to range from $11.9 billion to $12.0 billion, slightly above the previous range. Combined non-GAAP R&D;, AIPR&D;, and SG&A; expenses guidance is now set at $5.0 billion to $5.1 billion. This revised outlook incorporates accelerated povetacicept programs and increased investment in sales and marketing for JOURNAVX.

The non-GAAP effective tax rate guidance has also been lowered to 17% to 18%, from the prior 20.5% to 21.5%. This adjustment reflects one-time tax benefits recognized in Q3 2025 related to Alpine-related R&D; tax credits and anticipated recognition of previously deferred tax benefits in Q4 2025.